Celcuity Inc. (CELC)
NASDAQ (CM) NASDAQ (CM) Primary 
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
Perceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing. Meanwhile, the quarter-end position value rose by $169.16 million, reflecting both share additions and price movements.
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?
Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones.
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administration. A rebound in mergers and acquisitions (M&A) has also increased investor confidence in the industry.
3 Stocks You'll Wish You Bought Before 2026
Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that have posted impressive gains this year.
Celcuity: From Speculative Bet To Pre-Commercial Powerhouse
Celcuity has transitioned from a speculative biotech to a de-risked pre-commercial firm, driven by unprecedented Phase 3 VIKTORIA-1 trial results. Celcuity's gedatolisib demonstrated significant efficacy and a favorable safety profile in HR+/HER2- advanced breast cancer, supporting a strong investment thesis. With a completed NDA under the FDA's RTOR program and a $455M cash position, CELC is well-funded for commercialization and pipeline expansion.
Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript
Celcuity Inc. ( CELC ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Brian Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Apoorva Chaloori Maurice Raycroft - Jefferies LLC, Research Division Tara Bancroft - TD Cowen, Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Dara Azar - Stifel, Nicolaus & Company, Incorporated, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Jacob Soucheray - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity's Third Quarter 2025 Financial Results Webcast and Conference Call. [Operator Instructions] I would now like to turn the conference over to Apoorva Chaloori with ICR Healthcare.
Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results
Celcuity Inc. remains a Strong Buy, driven by positive Phase 3 VIKTORIA-1 data for gedatolisib in 2nd-line PIK3CA wild type HR+/HER2- advanced breast cancer patients. Company expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025, targeting wild-type PIK3CA advanced breast cancer patients. CELC can potentially move to targeting 1st-lne PIK3CA mutant and wild-type HR+/HER2- advanced breast cancer patients with ongoing phase 3 VIKTORIA-2 study.
Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript
Celcuity Inc. (NASDAQ:CELC ) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting October 20, 2025 8:00 AM EDT Company Participants Brian Sullivan - Co-Founder, Chairman & CEO Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Tara Bancroft - TD Cowen, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Gil Blum - Needham & Company, LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today.
Celcuity: Blink And You Missed It
Celcuity (CELC) surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer, affirming commercial potential. Gedatolisib shows significant progression-free survival benefits in VIKTORIA-1, with manageable discontinuation rates and a $5B market opportunity targeted by CELC. Recent fundraising and loan facilities secure CELC's cash runway into 2027, supporting NDA filing, potential approval, and initial launch.
